| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000021762 |
| Receipt No. | R000025098 |
| Scientific Title | Prospective study on the effectiveness assessment of Indocyanine Green Lymphography and Lymphatic Surgery for lymphedema and lymphatic disease. |
| Date of disclosure of the study information | 2016/04/03 |
| Last modified on | 2022/09/24 (Ver. 8) |
| Basic information | ||
| Public title | Prospective study on the effectiveness assessment of Indocyanine Green Lymphography and Lymphatic Surgery for lymphedema and lymphatic disease. | |
| Acronym | Prospective study on the effectiveness assessment of Indocyanine Green Lymphography and Lymphatic Surgery for lymphedema and lymphatic disease. | |
| Scientific Title | Prospective study on the effectiveness assessment of Indocyanine Green Lymphography and Lymphatic Surgery for lymphedema and lymphatic disease. | |
| Scientific Title:Acronym | Prospective study on the effectiveness assessment of Indocyanine Green Lymphography and Lymphatic Surgery for lymphedema and lymphatic disease. | |
| Region |
|
|
| Condition | |||||
| Condition | Lymphedema and lymphatic disease, chylous thoracs and ascites | ||||
| Classification by specialty |
|
||||
| Classification by malignancy | Others | ||||
| Genomic information | NO | ||||
| Objectives | |
| Narrative objectives1 | Using indocyanine green lymphography to investigate the pathology and the effectiveness of drug and radiological and surgical remedies in child lymphedema patients, lymphatic disease, chylo thoracs and ascites by analyzing pre-, intra-, and post-operative lymphatic assessments, comparing pre and postoperative changes, and assessing the associated clinical symptoms. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Explanatory |
| Developmental phase | Phase I |
| Assessment | |
| Primary outcomes | We analyze the assesment pre-operation and after treatment. Patient chart (name, patient ID, clinical history, pre and postoperative course, limb circumference, tissue stiffness); echogram, CT, MRI, lymphoscintigraphy, indocyanine green lymphography, and lymphoangiography obervations; blood test (complete blood count, chemistry, coagulation, blood type); histopathological analysis (collecting lymphatic vessel, adipose tissue, skin tissue, etc.); clinical photography (bilateral upper limbs for upper limb edema, bilateral lower limbs, abdominal, and inguinal area for lower limb lymphedema); health-related QOL analysis using Short Form (SF)-36 Health Survey; patient weight; general physical and image observations.And analysis of chylous and volume of chylous thoracs and ascites. |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |||
| No. of arms | 3 | ||
| Purpose of intervention | Treatment | ||
| Type of intervention |
|
||
| Interventions/Control_1 | Indocyanine green (ICG) lymphography and Lymphatic venous anastomosis(LVA) | ||
| Interventions/Control_2 | Indocyanine green (ICG) lymphography and drug treatment | ||
| Interventions/Control_3 | Indocyanine green (ICG) lymphography and radiological treatment | ||
| Interventions/Control_4 | |||
| Interventions/Control_5 | |||
| Interventions/Control_6 | |||
| Interventions/Control_7 | |||
| Interventions/Control_8 | |||
| Interventions/Control_9 | |||
| Interventions/Control_10 | |||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | All Subjects included in this study are lymphedema and lymphatic disease patients undergoing treatment at our department team (including collaboration with other hospital team) who have been fully informed consented. No age restriction and exclusion criteria were set. | |||
| Key exclusion criteria | Over 20 y.o. | |||
| Target sample size | 20 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Saiseikai Kawaguchi General Hospital | ||||||
| Division name | Department of Lymphatic and Reconstructive Surgery | ||||||
| Zip code | 332-8558 | ||||||
| Address | 5-11-5, Nishikawaguchi, Kawaguchi-shi, Saitama, Japan | ||||||
| TEL | 048-253-1551 | ||||||
| mihara-m@saiseikai.gr.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Saiseikai Kawaguchi General Hospital | ||||||
| Division name | Financial and legal department | ||||||
| Zip code | 332-8558 | ||||||
| Address | 5-11-5 Nishikawaguchi, Kawaguchi-shi, Saitama, Japan | ||||||
| TEL | 048-253-1551 | ||||||
| Homepage URL | |||||||
| zaimuhoumu@saiseikai.gr.jp | |||||||
| Sponsor | |
| Institute | Saiseikai Kawaguchi General Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | none |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Saiseikai Kawaguchi General Hospital |
| Address | Nishi-kawaguchi 5-11-5, Kawaguchi-shi, Saitamaken, Japan |
| Tel | 0482531551 |
| mihara33@yahoo.co.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | https://www.mominoki-shinryosho.jp/cellulitis/evidence/ |
| Publication of results | Unpublished |
| Result | |||||||
| URL related to results and publications | https://www.mominoki-shinryosho.jp/cellulitis/evidence/ | ||||||
| Number of participants that the trial has enrolled | 200 | ||||||
| Results | Preparing data | ||||||
| Results date posted |
|
||||||
| Results Delayed |
|
||||||
| Results Delay Reason | Preparing data | ||||||
| Date of the first journal publication of results | |||||||
| Baseline Characteristics | Preparing data | ||||||
| Participant flow | Preparing data | ||||||
| Adverse events | Preparing data | ||||||
| Outcome measures | Preparing data | ||||||
| Plan to share IPD | |||||||
| IPD sharing Plan description | |||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025098 |